Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety of IndoVac® as a Heterologous Booster Dose Against COVID-19 in Children 12-17 Years of Age

NCT05727215 is registered in ClinicalTrials.gov with PT Bio Farma as lead sponsor.

NCT NCT05727215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05727215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety of IndoVac® as a Heterologous Booster Dose Against COVID-19 in Children 12-17 Years of Age
Lead sponsor
PT Bio Farma
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2023
Completion date
March 18, 2024
Enrollment
150 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19